Our studies were fueled by the remarkable success of the FDA-approved p110-δ inhibitor idelalisib (Zydelig®) that exhibits significant activity for the treatment of chronic lymphocytic leukemia (CLL), relapsed of follicular non-Hodgkin's lymphoma (NHL) or small lymphocytic lymphoma (SLL) [19]. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.